ambroxol + salbutamol

Ambroxol + salbutamol is a fixed-dose combination therapy that integrates a mucolytic agent with a short-acting bronchodilator, primarily indicated for the management of respiratory disorders such as bronchial asthma and chronic obstructive pulmonary disease (COPD). Salbutamol acts as a selective beta-2 adrenergic receptor agonist, inducing rapid relaxation of bronchial smooth muscle to alleviate bronchospasm. Ambroxol serves as a secretolytic agent that reduces mucus viscosity by altering its chemical structure and stimulating the production of pulmonary surfactant by type II pneumocytes, which facilitates mucociliary clearance. This dual-action approach effectively addresses both airway obstruction and the accumulation of viscous secretions. Jinan Bainuo Pharmaceutical Technology Development Co., Ltd. is a recognized developer of this combination, particularly within the Chinese pharmaceutical market where it is formulated as oral tablets and solutions.

Brand names

Ambrolite-SSalmucolAmbrodil-SSalbetol-AMucosolvan Bronchodilator

Other names

ambroxol hydrochloride + salbutamol sulfate